Pemvidutide Research for MASH (Metabolic Dysfunction-Associated Steatohepatitis)
An evidence-based overview of research examining Pemvidutide in the context of mash (metabolic dysfunction-associated steatohepatitis). This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2b IMPACT trial showed 59.1% MASH resolution without fibrosis worsening at 48 weeks. 43.6% achieved fibrosis improvement of at least one stage. 82% reduction in liver fat by MRI-PDFF. FDA Fast Track designation granted November 2022.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for MASH (Metabolic Dysfunction-Associated Steatohepatitis)
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pemvidutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.